Supermodel Bambi Northwood-Blyth wears a Dexcom glucose monitor. So does your next-door neighbor with Type 2 diabetes and your fit-fluencer friend. Jake Leach, who took over as Dexcom CEO today, wants ...

Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...

Dexcom has won FDA clearance of the Smart Basal, a CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy. The clearance ...

Weeks after launching its first open call for diabetes advocates, Dexcom is spotlighting the resulting group of 16 people in a new awareness campaign. The project kicked off Friday, World Diabetes Day ...

Dexcom has issued a Class I recall for its G6 glucose sensor Android application due to a defect that causes the app to crash unexpectedly. As a result of the app terminating, users could miss ...

Dexcom has been hit by a major safety issue for an Android version of its G6 continuous glucose monitoring system app, leading the FDA to issue its most serious recall notice. A “software defect in ...

Dexcom recalled an Android app for its G6 continuous glucose monitor because of a problem with the app stopping unexpectedly. This story was originally published on MedTech Dive. To receive daily news ...

DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past ...

Oct 30 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring ...

SAN DIEGO (AP) — SAN DIEGO (AP) — DexCom Inc. (DXCM) on Thursday reported third-quarter net income of $283.8 million. The San Diego-based company said it had net income of 70 cents per share. Earnings ...

Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...